Unsafe
Not Aligned
Patient Risk:
High
Summary
Only a small portion of the listed claims can be assessed from the provided label excerpts (largely thyroid C-cell tumor/MTC contraindication and counseling). Most efficacy, dosing/timing, side-effect, administration, interaction, and meal-timing guidance claims are not supported or not present in the supplied FDA label text, so overall alignment is poor.
Category Scores
Accurate Statements
OZEMPIC/semaglutide has a labeled risk of thyroid C-cell tumors (MTC) based on rodent findings; human relevance is unknown; OZEMPIC is contraindicated in patients with personal/family history of MTC or MEN 2; patients should be counseled on symptoms; routine calcitonin/ultrasound monitoring is of uncertain value.
Supported by label excerpts: Contraindications (Section 4: personal/family history of MTC or MEN 2), Risk of Thyroid C-Cell Tumors (Section 5.1: rodent findings, human relevance unknown, symptom counseling, uncertainty of routine calcitonin/ultrasound monitoring), and Carcinogenesis (Section 13.1).
Unsupported Statements
Ozempic is a GLP-1 receptor agonist used to treat type 2 diabetes.
The provided label excerpts do not include the indication statement.
Ozempic improves blood sugar control.
The provided label excerpts do not include efficacy claims.
Ozempic is associated with weight loss.
The provided label excerpts do not include weight-loss/indication or efficacy statements.
Ozempic mimics the natural hormone GLP-1.
Not stated in the provided label excerpts.
Ozempic stimulates insulin production.
Not stated in the provided label excerpts.
Ozempic slows down gastric emptying.
Not stated in the provided label excerpts.
Ozempic improves glucose control.
Duplicate/derivative efficacy claim; not present in the provided label excerpts.
Ozempic reduces hunger.
Not stated in the provided label excerpts.
Ozempic increases feelings of fullness.
Not stated in the provided label excerpts.
Ozempic slows the emptying of the stomach, which can lead to a more gradual increase in blood sugar levels after meals.
Mechanism/efficacy relationship not stated in provided label excerpts.
Ozempic improves insulin sensitivity.
Not stated in the provided label excerpts.
Ozempic is designed to work in conjunction with a healthy diet and exercise plan.
Not stated in the provided label excerpts.
Adjusting meal times may not be necessary for everyone using Ozempic.
Not stated in the provided label excerpts.
Adjusting meal times can be beneficial for patients who experience hypoglycemia with Ozempic.
Not stated in the provided label excerpts.
Adjusting meal times can be beneficial for patients who have difficulty controlling their blood sugar levels.
Not stated in the provided label excerpts.
Eating meals at consistent times can help improve blood sugar control.
Not stated in the provided label excerpts.
Eating meals at consistent times can reduce the risk of hypoglycemia.
Not stated in the provided label excerpts.
Eating smaller, more frequent meals can increase feelings of fullness.
Not stated in the provided label excerpts.
Eating smaller, more frequent meals can reduce hunger.
Not stated in the provided label excerpts.
Adjusting meal times can help with weight loss by reducing overall calorie intake.
Not stated in the provided label excerpts.
Adjusting meal times can help with weight loss by increasing satiety.
Not stated in the provided label excerpts.
Ozempic can be taken with other medications.
No drug interaction statements or compatibility guidance provided in the excerpts.
Ozempic typically starts working within a few weeks of treatment.
No onset/timing of effect statement provided in the excerpts.
Ozempic may take several months to achieve optimal results.
No onset/duration-of-response statement provided in the excerpts.
Common side effects of Ozempic include nausea.
No adverse reaction frequency list provided in the excerpts.
Common side effects of Ozempic include vomiting.
No adverse reaction frequency list provided in the excerpts.
Common side effects of Ozempic include injection site reactions.
No adverse reaction frequency list provided in the excerpts.
The reported side effects of Ozempic are typically mild and temporary.
No characterization of severity/duration provided in the excerpts.
Sudden discontinuation of Ozempic can lead to adverse effects.
No discontinuation warning or withdrawal guidance provided in the excerpts.
It is necessary to consult with a healthcare provider before stopping Ozempic.
Not stated in the provided label excerpts.
Ozempic is typically prescribed for long-term use.
No duration-of-use guidance provided in the excerpts.
Ozempic effectiveness should be monitored and treatment adjusted as needed by a healthcare provider.
No monitoring/titration guidance provided in the excerpts.
Contradictions
Important Omissions
The provided list omits, for the majority of safety-related statements, whether specific contraindications and boxed/warning details beyond thyroid C-cell tumors (e.g., other contraindications/warnings) are addressed. This omission is material when making broad safety or discontinuation/administration claims without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many claims (efficacy, meal-timing/hypoglycemia risk reduction, side-effect frequency/severity, discontinuation effects, long-term use) are not supported by the supplied label excerpts. Unsupported guidance could mislead patients/clinicians about management and expected adverse effects.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA label excerpts; only thyroid C-cell tumor/MTC-related contraindication and counseling are clearly supported.
Suggested Improvement
Limit claims to label-supported sections provided (e.g., Section 4 contraindication and Section 5.1/13.1 boxed-warning-related thyroid C-cell tumor risk and counseling/uncertainty of routine calcitonin/ultrasound). Remove or replace meal-timing, hypoglycemia-risk reduction, onset-of-action, adverse reaction frequency/severity, discontinuation guidance, and general efficacy/mechanism statements unless the corresponding label text is supplied.